Cargando…
Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer
Whether ICIs combined with chemotherapy can improve outcomes in EGFR-mutant non-small cell lung cancer (NSCLC) remains uncertain. Patients with EGFR-mutant NSCLC and who progressed on first-line EGFR-TKIs treatment were retrospectively collected. We reviewed the outcome of these patients treated wit...
Autores principales: | Shen, Chia-I, Chao, Heng-Sheng, Shiao, Tsu-Hui, Chiang, Chi-Lu, Huang, Hsu-Ching, Luo, Yung-Hung, Chiu, Chao-Hua, Chen, Yuh-Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352947/ https://www.ncbi.nlm.nih.gov/pubmed/34373555 http://dx.doi.org/10.1038/s41598-021-95628-w |
Ejemplares similares
-
Real-world evidence of the intrinsic limitations of PCR-based EGFR mutation assay in non-small cell lung cancer
por: Shen, Chia-I, et al.
Publicado: (2022) -
Old age and
EGFR
mutation status in inoperable early‐stage non‐small cell lung cancer patients receiving stereotactic ablative radiotherapy: A single institute experience of 71 patients in Taiwan
por: Wu, Yuan‐Hung, et al.
Publicado: (2023) -
Efficacy of different platforms in detecting EGFR mutations using cerebrospinal fluid cell‐free DNA from non‐small‐cell lung cancer patients with leptomeningeal metastases
por: Chiang, Chi‐Lu, et al.
Publicado: (2023) -
Lysine Deprivation Induces AKT-AADAT Signaling and Overcomes EGFR-TKIs Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells
por: Hsu, Chia-Chi, et al.
Publicado: (2021) -
Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
por: Chen, Ya, et al.
Publicado: (2021)